Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Acth Stimulation Test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Acth Stimulation Test. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2006-004111-22 Sponsor Protocol Number: CSOM230B2305 Start Date*: 2007-01-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind study to assess the safety and efficacy of different dose levels of Pasireotide (SOM230) s.c. over a 6 month treatment period in patients with de novo, persistent or recu...
    Medical condition: Cushing’s disease is rare disease that is caused by an adrenocorticotropic hormone (ACTH) secreting pituitary adenoma. The elevated ACTH secreted by these tumors stimulates the adrenal glands to pr...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) IT (Completed) FI (Completed) FR (Completed) DE (Completed) PT (Completed) GR (Completed) GB (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2021-006184-19 Sponsor Protocol Number: SPI-62-CL-2001 Start Date*: 2022-06-22
    Sponsor Name:Sparrow Pharmaceuticals, Inc.
    Full Title: SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing’s Syndrome
    Medical condition: Cushing’s Syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.1 10014698 - Endocrine disorders 10035109 Pituitary-dependent Cushing's syndrome PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BG (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2009-011128-70 Sponsor Protocol Number: CSOM230G2304 Start Date*: 2011-08-24
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, multicentre, phase III study to evaluate the efficacy and safety of pasireotide LAR in patients with Cushing’s disease
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004860 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) DE (Completed) NL (Completed) BE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2010-024165-44 Sponsor Protocol Number: CSOM230B2406 Start Date*: 2011-08-05
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label, multi-center, expanded access study of pasireotide s.c. in patients with Cushing’s disease (Seascape)
    Medical condition: Cushing’s disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 10014698 - Endocrine disorders 10011651 Cushing's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GR (Prematurely Ended) ES (Completed) CZ (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2007-005018-37 Sponsor Protocol Number: Start Date*: 2008-01-18
    Sponsor Name:Amar Agha
    Full Title: Optimal glucocorticoid replacement therapy in adrenocorticotropin (ACTH) deficient hypopituitary patients
    Medical condition: 10 male patients with hypopituitarism resulting in ACTH (adrenocorticotropin) deficiency (ICD E23.0) will be studied on varying doses of hydrocortisone replacement therapy. THis is not a new medica...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021067 Hypopituitarism LLT
    9.1 10033662 Panhypopituitarism LLT
    9.1 10057217 Isolated ACTH deficiency LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-001437-12 Sponsor Protocol Number: Ex17 Start Date*: 2017-06-12
    Sponsor Name:University of Tartu
    Full Title: Effect of exenatide on cortisol secretion
    Medical condition: Healthy volunteers
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: EE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-001768-30 Sponsor Protocol Number: HYSS 3 Start Date*: 2006-01-04
    Sponsor Name:EM-kliniken
    Full Title: Comparison of 2 and 4 doses hydrocortison substitution with regard to plasma concentration and quality of life.
    Medical condition: We aim to study patients with cortisol deficiency caused by primary adrenal insufficiency (Addison’s disease of autoimmune origin).
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007337-49 Sponsor Protocol Number: CLCI699A2215 Start Date*: 2009-02-18
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase II, randomized, double-blind, placebo controlled, multi-center study to evaluate the effects of LCI699 on cortisol in patients with hypertension.
    Medical condition: hypertension
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020772 Hypertension LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: View results
    EudraCT Number: 2013-002133-37 Sponsor Protocol Number: COR-2012-01 Start Date*: 2014-11-17
    Sponsor Name:Cortendo AB
    Full Title: An Open Label Study to Assess the Safety and Efficacy of COR—003 (2S, 4R-Ketoconazole) in the Treatment of Endogenous Cushing’s Syndrome
    Medical condition: Endogenous Cushing's syndrome (CS) or Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004860 10011657 Cushings syndrome LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) ES (Completed) BE (Completed) NL (Completed) SE (Completed) DK (Completed) DE (Completed) IT (Completed) BG (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-004766-34 Sponsor Protocol Number: CLCI699C2301 Start Date*: 2014-08-01
    Sponsor Name:NOVARTIS FARMA S.p.A.
    Full Title: A Phase III, multi-center, double-blind, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of...
    Medical condition: Cushing's disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (Completed) DE (Completed) AT (Completed) ES (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2009-014909-14 Sponsor Protocol Number: CS/München01 Start Date*: Information not available in EudraCT
    Sponsor Name:Max-Planck-Institut für Psychiatrie
    Full Title: Neuropsychological effects of hydrocortisone substitution in patients with partial adrenal insufficiency after traumatic brain injury or subarachnoidal haemorrhage
    Medical condition: hormonal deficiency after traumatic-brain- injury (TBI) or subarachnoidal haemorrhage (SAH)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011198 Cortisol decreased LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-005640-14 Sponsor Protocol Number: 42994 Start Date*: 2013-04-15
    Sponsor Name:Erasmus MC
    Full Title: The effects of hormonal contraception on the HPA-axis functioning
    Medical condition: healthy female volunteers; hormonal contraception method used: combined method (oestrogens en progestins) and progesterone-only method.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004865 10010812 Contraceptive methods female HLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005501-22 Sponsor Protocol Number: LEO 80190-O23 Start Date*: 2008-04-22
    Sponsor Name:LEO Pharma A/S
    Full Title: Effect of Calcipotriol Plus Hydrocortisone Ointment on the HPA Axis and Calcium Metabolism in Patients with Psoriasis Vulgaris on the Face and on the Intertriginous Areas
    Medical condition: Psoriasis vulgaris on the face and on the intertriginous areas. The face is defined as: forehead including hairline, cheeks, nose, chin and ears (excluding the auditory meatus). In case of baldnes...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10050576 Psoriasis vulgaris LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-002240-17 Sponsor Protocol Number: ATR-101-301 Start Date*: 2017-05-16
    Sponsor Name:Millendo Therapeutics, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study of ATR-101 for the Treatment of Cushing’s Syndrome
    Medical condition: endogenous Cushing’s syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 10014698 - Endocrine disorders 10014698 Endocrine disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-010918-30 Sponsor Protocol Number: 2377 Start Date*: 2009-08-11
    Sponsor Name:Amar Agha, Beaumont Hospital
    Full Title: Effect of growth hormone replacement on cortisol-to-cortisone interconversion in hypopituitary patients with growth hormone deficiency and the influence of different aetiologies of hypopituitarism.
    Medical condition: 20 patients with hypopituitarism including growth hormone deficiency will be evaluated both on growth hormone replacement and when they have been off it for a 2 month period. They will have been pr...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10021067 Hypopituitarism LLT
    9.1 10033662 Panhypopituitarism LLT
    9.1 10056438 Growth hormone deficiency LLT
    9.1 10011318 Craniopharyngioma LLT
    9.1 10036832 Prolactinoma LLT
    9.1 10011651 Cushing's disease LLT
    9.1 10035104 Pituitary tumour LLT
    9.1 10061538 Pituitary tumour benign LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: IE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-003367-40 Sponsor Protocol Number: 2007/049/HP Start Date*: 2009-03-03
    Sponsor Name:CHU de Rouen
    Full Title: Pilot study of the effect of a substance P antagonist, aprepitant, on aldosterone and cortisol secretions in healthy volunteers
    Medical condition: The aim is to measure plasma aldosterone and cortisol concentrations in basal conditions and in response to different stimulation tests of the adrenal function
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-000384-26 Sponsor Protocol Number: BPLG-005 Start Date*: 2005-11-10
    Sponsor Name:LG Life Science Ltd. [...]
    1. LG Life Science Ltd.
    2. BioPartners
    Full Title: A phase III, double-blind, randomized, placebo-controlled, parallel-group, multicenter study to assess efficacy and safety of LB03002 administered weekly in adults with growth hormone deficiency.
    Medical condition: growth hormone deficiency in adults
    Disease: Version SOC Term Classification Code Term Level
    8.0 10056438 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) ES (Ongoing) SE (Completed) CZ (Completed) GB (Completed) SK (Completed) FR (Completed) DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-018074-56 Sponsor Protocol Number: G0900001:RoSAv1.1:12_09 Start Date*: 2010-05-05
    Sponsor Name:Newcastle upon Tyne Hospitals NHS Foundation Trust
    Full Title: Revival of autochthonous adrenocortical stem cells in autoimmune Addison’s disease (RoSA)
    Medical condition: Autoimmune Addison's disease
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001343 Adrenal cortical hypofunction HLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-003678-82 Sponsor Protocol Number: CHDR0606 Start Date*: 2007-07-10
    Sponsor Name:Centre for Human Drug Research
    Full Title: Pharmacokinetics and effects of oral clonidine in children with suspected Growth Hormone deficiency
    Medical condition: Clonidine is studied in the paediatric population, more specific children with short stature. It is used as a diagnostic tool to establish Growth Hormone reserve in routine practice.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10005573 Blood growth hormone decreased LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2010-022403-22 Sponsor Protocol Number: CLCI699C2201 Start Date*: 2011-07-04
    Sponsor Name:NOVARTIS FARMA
    Full Title: A proof-of concept, open-label, forced titration, multicenter study to assess the safety/tolerability and efficacy of 10-weeks treatment of LCI699 in patients with Cushing’s disease
    Medical condition: Cushing's disease
    Disease: Version SOC Term Classification Code Term Level
    14.0 10014698 - Endocrine disorders 10011652 Cushing's syndrome PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon May 20 01:45:39 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA